Close Menu

NEW YORK – Alzheimer's disease testing firm ADx Healthcare said today that it has partnered with Osaka, Japan-based Nakanoshima Clinic and Ixlayer, a San Francisco health IT company, to launch a polygenic-risk score for early detection of Alzheimer’s disease in Japan.

The test, called GenoRisk, assays 32 genetic loci, with results analyzed and interpreted by ADx Healthcare's medical team. According to the firm's CEO Steve Booth, the panel included both risk-associated and protective genes that influence Alzheimer's disease risk.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.